FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Title

FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma.

Authors

Keywords

-

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 34, Issue 18_suppl, Pages LBA4001-LBA4001

Publisher

American Society of Clinical Oncology (ASCO)

Online

2017-05-12

DOI

10.1200/jco.2016.34.18_suppl.lba4001